$11.13
-0.01000-0.09%
At close: -
$11.13
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Enfusion Analyst Ratings and Price Targets | NYSE:ENFN | Benzinga
Enfusion Inc has a consensus price target of $10.39 based on the ratings of 10 analysts. The high is $13 issued by Stifel on December 18, 2024. The low is $8 issued by Goldman Sachs on February 28, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Stifel, and B of A Securities on December 23, 2024, December 18, 2024, and March 13, 2024, respectively. With an average price target of $11.17 between Piper Sandler, Stifel, and B of A Securities, there's an implied 0.33% upside for Enfusion Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Stifel
B of A Securities
Goldman Sachs
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Enfusion
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/13/2025 | Buy Now | — | William Blair | Bhavan Suri42% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 12/23/2024 | Buy Now | 3.32% | Piper Sandler | Sumeet Mody86% | $10 → $11.5 | Maintains | Neutral | Get Alert |
| 12/18/2024 | Buy Now | 16.8% | Stifel | Parker Lane47% | $11 → $13 | Maintains | Buy | Get Alert |
| 03/13/2024 | Buy Now | -19.14% | B of A Securities | Koji Ikeda57% | $8 → $9 | Maintains | Underperform | Get Alert |
| 02/28/2024 | Buy Now | -28.12% | Goldman Sachs | Gabriela Borges65% | $9 → $8 | Downgrade | Neutral → Sell | Get Alert |
| 01/30/2024 | Buy Now | -19.14% | JP Morgan | Alexei Gogolev73% | $11 → $9 | Downgrade | Neutral → Underweight | Get Alert |
| 12/20/2023 | Buy Now | -10.15% | Piper Sandler | Sumeet Mody86% | $9 → $10 | Maintains | Neutral | Get Alert |
| 11/07/2023 | Buy Now | -19.14% | UBS | Kevin Mcveigh55% | → $9 | Initiates | → Neutral | Get Alert |
| 08/09/2023 | Buy Now | -10.15% | Goldman Sachs | Gabriela Borges65% | $11.5 → $10 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | -1.17% | Morgan Stanley | James Faucette66% | $12 → $11 | Maintains | Overweight | Get Alert |
| 05/22/2023 | Buy Now | -19.14% | Piper Sandler | Sumeet Mody86% | $11 → $9 | Maintains | Neutral | Get Alert |
| 05/10/2023 | Buy Now | -1.17% | Credit Suisse | Kevin Mcveigh55% | $14 → $11 | Maintains | Neutral | Get Alert |
| 04/03/2023 | Buy Now | -1.17% | Piper Sandler | Sumeet Mody86% | → $11 | Initiates | → Neutral | Get Alert |
| 03/15/2023 | Buy Now | 7.82% | JP Morgan | Alexei Gogolev73% | → $12 | Initiates | → Neutral | Get Alert |
| 01/26/2023 | Buy Now | -14.65% | Goldman Sachs | Gabriela Borges65% | $14 → $9.5 | Maintains | Neutral | Get Alert |
| 01/04/2023 | Buy Now | -10.15% | B of A Securities | Koji Ikeda57% | $15 → $10 | Downgrade | Neutral → Underperform | Get Alert |
| 01/03/2023 | Buy Now | 7.82% | Morgan Stanley | James Faucette66% | $13 → $12 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/03/2022 | Buy Now | 34.77% | B of A Securities | Koji Ikeda57% | $17 → $15 | Downgrade | Buy → Neutral | Get Alert |
| 08/10/2022 | Buy Now | 16.8% | Morgan Stanley | James Faucette66% | $8 → $13 | Maintains | Equal-Weight | Get Alert |
| 07/14/2022 | Buy Now | 7.82% | Goldman Sachs | Gabriela Borges65% | $14 → $12 | Maintains | Neutral | Get Alert |
| 07/06/2022 | Buy Now | 7.82% | Piper Sandler | Christopher Donat47% | $15 → $12 | Maintains | Overweight | Get Alert |
| 05/13/2022 | Buy Now | -28.12% | Morgan Stanley | James Faucette66% | $18 → $8 | Maintains | Equal-Weight | Get Alert |
| 05/13/2022 | Buy Now | 43.76% | Credit Suisse | Kevin Mcveigh55% | $20 → $16 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Enfusion (ENFN) stock?
The latest price target for Enfusion (NYSE:ENFN) was reported by William Blair on January 13, 2025. The analyst firm set a price target for $0.00 expecting ENFN to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enfusion (ENFN)?
The latest analyst rating for Enfusion (NYSE:ENFN) was provided by William Blair, and Enfusion downgraded their market perform rating.
When was the last upgrade for Enfusion (ENFN)?
The last upgrade for Enfusion Inc happened on January 3, 2023 when Morgan Stanley raised their price target to $12. Morgan Stanley previously had an equal-weight for Enfusion Inc.
When was the last downgrade for Enfusion (ENFN)?
The last downgrade for Enfusion Inc happened on January 13, 2025 when William Blair changed their price target from N/A to N/A for Enfusion Inc.
When is the next analyst rating going to be posted or updated for Enfusion (ENFN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enfusion, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enfusion was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.
Is the Analyst Rating Enfusion (ENFN) correct?
While ratings are subjective and will change, the latest Enfusion (ENFN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Enfusion (ENFN) is trading at is $11.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.